Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18577912 | 0.89 | CA12 (0.39) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL15899125 | 0.86 | CYP3A4 (0.37) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL18589182 | 0.82 | CA12 (0.42) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14822583 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL26657808 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14822595 | 0.81 | LMNA (0.43) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14822353 | 0.78 | CA12 (0.39) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL18823118 | 0.78 | CA12 (0.47) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL18589129 | 0.76 | CA12 (0.38) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL29705195 | 0.75 | CA12 (0.37) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759538-B1 | RADIOACTIVE FLUORINE LABELED COMPOUND | NIHON MEDIPHYSICS CO LTD (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9107964-B2 | Radioactive fluorine-labeled compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140364620-A1 | RADIOACTIVE FLUORINE-LABELED COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-2759538-A1 | RADIOACTIVE FLUORINE LABELED COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2014-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364620-A1 | RADIOACTIVE FLUORINE-LABELED COMPOUND | AFF1, PRMT1, DOT1L | CA12 1215/4885CA1 667/4885CA2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.